M&A / Deals

• M&A / Deals

MSD concludes Terns acquisition to expand CML pipeline

pharminent May 6, 2026

• M&A / Deals

Latus Bio secures $97m in funding to boost gene therapy access

pharminent May 5, 2026

• M&A / Deals

Autoimmune disease biotech Odyssey sets terms for $225m IPO

pharminent May 5, 2026

• M&A / Deals

Cytospire hauls in $83M for a new type of T cell engager

pharminent May 5, 2026

• M&A / Deals

Amneal Agrees to Acquire Kashiv BioSciences for Total Payment up to $1.1 Billion

pharminent May 4, 2026

• M&A / Deals

Eli Lilly to Acquire Kelonia Therapeutics

pharminent May 4, 2026

• M&A / Deals

UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases

pharminent May 4, 2026

• M&A / Deals

LEO Pharma to acquire gene therapy company Replay

pharminent May 1, 2026

• M&A / Deals

Two biotechs raise a combined $556M in latest spurt of IPOs

pharminent May 1, 2026

• M&A / Deals

Parexel buys Vitrana to boost patient safety toolkit

pharminent April 30, 2026

• M&A / Deals

Teva makes its first M&A play in years, buying Emalex

pharminent April 30, 2026

• M&A / Deals

Avalyn, in pursuit of better lung drugs, banks $300M in an IPO

pharminent April 30, 2026

• M&A / Deals

Chiesi to buy KalVista in $1.9B deal for rare disease drug

pharminent April 29, 2026

• M&A / Deals

Eli Lilly bets on recombinases in $2.25bn Profluent R&D pact

pharminent April 29, 2026

• M&A / Deals

Arcera and Fosun sign MoU for neuroscience innovation

pharminent April 29, 2026

• M&A / Deals

Rocket to sell PRV for $180m to advance gene therapy pipeline

pharminent April 29, 2026

• M&A / Deals

AbbVie sinks talons into KRAS with right to buy Kestrel for up to $1.45B

pharminent April 28, 2026

• M&A / Deals

Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine ‘holy grail’

pharminent April 28, 2026

• M&A / Deals

Coultreon banks $125M to support testing of former Galapagos immune drug

pharminent April 28, 2026

• M&A / Deals

Merck KGaA and Remepy join forces to develop combo drug-digital therapies

pharminent April 28, 2026

• M&A / Deals

BioMarin acquires Amicus Therapeutics for $4.8bn

pharminent April 28, 2026

• M&A / Deals

Eli Lilly acquires Ajax Therapeutics for first-in-class JAK2 inhibitor in myelofibrosis

pharminent April 27, 2026

• M&A / Deals

Sun Pharma to acquire Organon for $11.75bn

pharminent April 27, 2026

• M&A / Deals

Sun sets out $11.75bn takeover play for Organon

pharminent April 27, 2026

• M&A / Deals

Avalyn seeks public debut to support new lung drug formulations

pharminent April 24, 2026

• M&A / Deals

OZMOSI and Planview partner to enhance pharmaceutical data integration

pharminent April 24, 2026

• M&A / Deals

Cumberland to sell drug portfolio to Apotex for $100m

pharminent April 24, 2026

• M&A / Deals

Cumberland to sell drug portfolio to Apotex for $100m

pharminent April 24, 2026

• M&A / Deals

Lilly exits Rigel alliance, adding to RIPK1 scrap heap

pharminent April 22, 2026

• M&A / Deals

MSD-backed Ray locks in $125m to back eye drug pipeline

pharminent April 22, 2026

• M&A / Deals

BioAegis and Prenosis partner for inflammatory disease therapies

pharminent April 22, 2026

• M&A / Deals

BioAegis and Prenosis partner for inflammatory disease therapies

pharminent April 22, 2026

• M&A / Deals

Tortugas debuts with $106M and brain drugs from Hansoh, Eisai

pharminent April 21, 2026

• M&A / Deals

Tortugas takes neuro deep dive with $106M to develop Eisai, Hansoh programs

pharminent April 21, 2026

• M&A / Deals

Eli Lilly doubles down on in vivo with $7bn Kelonia buyout

pharminent April 21, 2026

• M&A / Deals

Asahi Kasei acquires German company Aicuris

pharminent April 21, 2026

• M&A / Deals

Asahi Kasei acquires German company Aicuris

pharminent April 21, 2026

• M&A / Deals

Lilly boosts ‘in vivo’ cell therapy capabilities with Kelonia buyout

pharminent April 20, 2026

• M&A / Deals

Lilly adds gene delivery technology to CAR T in up to $7B Kelonia deal

pharminent April 20, 2026

• M&A / Deals

Update: Lilly makes $7bn bid for in vivo CAR-T firm Kelonia

pharminent April 20, 2026